Now he preaches it himself. Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

While AstraZeneca confirmed no current jobs at the Speke site would be affected, the cancellation raises questions about Britain's investment climate. The Chancellor has recently attempted to shift ...

Confirming the reversal on Friday, a spokesperson for AstraZeneca said: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke. "Several factors ...

AstraZeneca has pulled out of plans to build a new £450m facility in Liverpool. AstraZeneca, which produced one of the Covid-19 jabs, has an existing site on Renaissance Way, Speke and during the ...

This is hardly the first time AstraZeneca has bristled at the U.K.’s business environment for the life sciences industry. Back in February 2023, AZ CEO Pascal Soriot attributed the company’s ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

MANILA, Philippines — Trade Secretary Cristina Roque reported on Saturday that the British-Swedish pharmaceutical AstraZeneca expressed interest in conducting most of its clinical trials in the ...

As­traZeneca says it plans to par­tic­i­pate in the next round of Medicare ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act. But this time around, the com­pa­ny says … ...

FDA approves AstraZeneca's Datroway, reducing breast cancer progression risk by 37% per TROPION-Breast01 trial results. Datroway's safety profile remains consistent, with 4.2% ILD rate ...